LENZ Therapeutics (LENZ) Cash & Equivalents (2020 - 2026)

LENZ Therapeutics (LENZ) has reported Cash & Equivalents for 7 consecutive years, with $24.8 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Equivalents rose 7.51% year-over-year to $24.8 million; the TTM figure through Mar 2026 stood at $24.8 million (up 7.51% YoY), while the FY2025 annual figure was $25.2 million, up 24.91% from the prior year.
• Cash & Equivalents declined to $24.8 million in Q1 2026 per LENZ's latest filing, from $25.2 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $200.4 million in Q1 2024 and bottomed at $8.0 million in Q1 2023.
• Historically, Cash & Equivalents has averaged $72.1 million across 5 years, with a median of $39.3 million in 2024.
• Annual changes were most pronounced in 2023 — Cash & Equivalents sank 95.7% — and 2024, when it soared 2416.42%.
• LENZ Therapeutics' Cash & Equivalents stood at $56.4 million in 2022, then slumped by 37.69% to $35.1 million in 2023, then sank by 42.64% to $20.2 million in 2024, then increased by 24.91% to $25.2 million in 2025, then decreased by 1.62% to $24.8 million in 2026.
• Business Quant data shows LENZ's Cash & Equivalents at $24.8 million in Q1 2026, $25.2 million in Q4 2025, and $25.4 million in Q3 2025.